Compare Goodyear Tire & Rubber Co (GT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs State Street SPDR S&P Biotech ETF — how do they compare? Goodyear Tire & Rubber Co trades at $7.22 (market cap $1.94B), while State Street SPDR S&P Biotech ETF trades at $154.26. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| GT | XBI | |
|---|---|---|
Market Cap | $1.94B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $11.54 | $164.28 |
52-Week Low | $5.58 | $85.16 |
Enterprise Value | $9.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $6.66, up 0.3% with neutral technical signals. The stock shows mixed fundamentals with attractive valuation ratios (P/E 4.69, P/B 0.64) but negative profitability (ROE -52.56%, net margin -11.64%). Recent Q1 2026 earnings beat estimates despite a loss, while the company transitions to S&P SmallCap 600. Cash flow improved in 2025 with $46M net inflow, though revenue declined to $18.28B.
Outlook remains challenging with declining revenue and negative margins, though deep value metrics and analyst consensus target of $8.75 suggest upside potential. Key risks include persistent operational headwinds, weak tire demand, and high debt levels. The Goodyear Forward program and lunar tire contract provide strategic catalysts amid competitive pressures.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
